The $5 Million Bet on Indian Skin Science
On May 4, 2026, a Chennai-based skincare startup announced a funding round that said as much about the changing Indian beauty market as it did about the company itself . CHOSEN, founded by cosmetic dermatologist Dr Renita Rajan, raised $5 million in a Series A round led by Fireside Ventures, with participation from BOLD, L'Oréal's corporate venture capital fund, and Alkemi Growth Capital .
The round also included angel investor Avnish Anand, co-founder and former CEO of CaratLane, along with a cohort of practising dermatologists: Dr Chandan Asokan, Dr KC Nischal, Dr Punit Saraogi, Dr Nishita Ranka, and Dr Mikki Singh . The presence of these dermatologists as investors is not symbolic. It reflects the brand's core thesis: that clinical credibility, not just marketing spend, is the foundation of lasting consumer trust in skincare.
With this round, CHOSEN's total funding has surpassed $6 million, including $1.2 million raised from friends and family in 2024 . The fresh capital will be used to strengthen research and development capabilities, expand the pipeline of clinically validated products, scale its dermatologist-led Centre of Excellence, and hire talent across functions .
The Problem: Skincare Formulated for the Wrong Skin
For decades, the premium skincare market in India has been dominated by imported brands that formulate for Caucasian or East Asian skin types. Melanin-rich Indian skin has different needs: higher susceptibility to pigmentation, different patterns of ageing, and unique responses to environmental stressors like pollution and UV radiation.
Dr Renita Rajan, a practising cosmetic dermatologist, saw this gap firsthand in her clinic. She founded CHOSEN in 2020 to address what she describes as the disconnect between dermatological expertise and the personal care products available to Indian consumers . Personal care in India has largely followed global trends that don't fully reflect local conditions, she told YourStory. The company is building products grounded in the Indian exposome and genome, with dermatology at the core .
The concept of the exposome—the totality of environmental and lifestyle factors that influence skin health—is central to CHOSEN's approach. Rather than applying formulations developed for other climates and genetic profiles, the brand studies how Indian skin responds to local conditions and develops solutions accordingly .
The Solution: A Clinic-to-Consumer Model
CHOSEN operates what it calls a clinic-to-consumer model, combining dermatologist-led product development with direct consumer distribution . Products are prescribed in dermatology clinics, creating what the company describes as a trust-led flywheel: dermatologists recommend products they have confidence in, consumers experience visible results, and repeat purchases follow.
The brand's portfolio spans topical formulations and nutraceuticals, targeting four key domains of skin ageing: pigmentation, texture, contour, and hair ageing . Its flagship offerings include SAFESCREEN NEXGEN sunscreen and the CHOSEN Sculpt protocol, a clinically validated topical contour system designed specifically for Indian women . The company currently sells over 55 stock-keeping units through its website and doctor-led channels .
The clinic-to-consumer model differentiates CHOSEN from mass-market direct-to-consumer beauty brands that rely primarily on influencer marketing and advertising. By anchoring its growth in professional recommendation, the brand builds what investors call a moat: clinical validation that cannot be replicated by marketing budgets alone.
Why L'Oréal's BOLD Placed the Bet
The participation of L'Oréal's corporate venture capital arm, BOLD, is the most significant signal in this funding round. L'Oréal, the world's largest beauty company, does not invest lightly in early-stage startups. Its decision to back CHOSEN reflects both confidence in the brand's fundamentals and a broader strategic interest in India's dermocosmetics market.
Samantha Etienne, global general manager of BOLD, explained the investment rationale. She said that in the very dynamic Indian beauty market, BOLD believes CHOSEN has the potential to contribute to shaping the future of dermocosmetics in India . The fund saw a unique model at the intersection of science and a deeply embedded dermatologist network .
BOLD's involvement also gives CHOSEN access to L'Oréal's global expertise in product development, regulatory affairs, and distribution. For a six-year-old startup, that kind of strategic backing is arguably more valuable than the capital itself.
The investment continues L'Oréal's broader push into dermatological beauty, a segment that has become one of the group's primary growth drivers. L'Oréal's dermatological beauty division grew by 5.5 percent in 2025, driven by brands like La Roche-Posay and CeraVe, which have successfully scaled models based on science, professional recommendation, and consumer trust . CHOSEN reproduces this logic in an emerging market, with a local approach from its origin.
The Investor Rationale: Clinical Rigor Meets Consumer Trust
The other investors in the round echoed similar themes. Varun Varma, principal at Fireside Ventures, said what drew the fund to CHOSEN is the rare combination of deep clinical rigour and a trust-led go-to-market that few consumer brands have cracked . He added that the brand stands out for combining clinical credibility with strong consumer traction .
Alka Goel, founding partner at Alkemi Growth Capital, pointed to the brand's differentiated positioning in a fast-growing market. She said that given CHOSEN's dermatology-first and R&D-led positioning in a fast-growing dermaceutical market, the startup is well placed to address the unmet needs of skin of colour .
Avnish Anand, the CaratLane co-founder who participated as an angel investor, framed his decision in terms of founder quality. He stated that he believes in backing founders who are deeply committed to building differentiated, product-led businesses, and that CHOSEN reflects this ethos through its strong science-led approach and focus on innovation in skincare .
The Market Opportunity
The funding comes at a time when investor interest in specialised beauty and skincare startups in India is rising, particularly brands building products tailored to local consumer needs rather than global formulations . The Indian beauty and personal care market is one of the fastest-growing in the Asia-Pacific region, with the premium segment attracting significant capital toward brands like Sugar Cosmetics, Plum, Mamaearth (Honasa), and Minimalist .
CHOSEN competes in the dermocosmetics segment—products positioned at the intersection of pharmaceuticals and cosmetics—against established international brands such as Heliocare, Obagi Medical, Bioderma, and Cetaphil, as well as domestic players like The Derma Co and Dr. Sheth's .
What distinguishes CHOSEN is its founder's clinical credentials and the brand's deep integration with practising dermatologists. While many beauty brands claim to be dermatologist-recommended, CHOSEN was built by a dermatologist, for dermatologists to prescribe. That distinction matters in a market where consumers are increasingly skeptical of marketing claims and hungry for clinical validation.
The Use of Funds: R&D, Talent, and Scale
With the fresh capital, CHOSEN plans to deepen its research and development capabilities, expand its pipeline of clinically validated products, and scale its dermatologist-led Centre of Excellence . The company also intends to hire across functions as it builds out its product and clinical infrastructure .
The focus on R&D is strategic. In the dermocosmetics segment, product efficacy is the primary driver of repeat purchases. Brands that cannot demonstrate visible results do not survive. By investing in clinical research and evidence generation, CHOSEN is building a defensible advantage that cannot be easily copied by newer entrants.
The company is headquartered in Chennai and operates across skincare, haircare, and wellness categories . Its products are available through its own website and through dermatologist-led channels, with plans to expand distribution as the brand scales.
The Bigger Picture: What This Means for Indian Beauty
CHOSEN's Series A round is not just a funding story. It is a signal that the Indian beauty market is maturing in two important ways.
First, consumers are becoming more discerning. The days when Indian buyers defaulted to imported brands because domestic options felt inferior are ending. A new generation of consumers wants products formulated for their skin, their climate, and their lifestyle. They are willing to pay a premium for science-backed solutions that actually work.
Second, investors are recognising that the next wave of beauty brands will be built differently. The era of heavy influencer marketing and rapid category expansion is giving way to a focus on clinical credibility, product efficacy, and sustainable unit economics. CHOSEN fits this new template: founded by a domain expert, backed by practising dermatologists, and anchored in research rather than hype.
Varun Varma of Fireside Ventures captured this shift when he said that few consumer brands have cracked the combination of deep clinical rigour and trust-led distribution. CHOSEN has. And with $5 million in fresh capital and L'Oréal's strategic backing, it now has the runway to prove that this model can scale.
